Comparative Pharmacology
Head-to-head clinical analysis: NANDROLONE PHENPROPIONATE versus WINSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NANDROLONE PHENPROPIONATE versus WINSTROL.
NANDROLONE PHENPROPIONATE vs WINSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nandrolone phenpropionate is an anabolic steroid that binds to androgen receptors, activating gene expression leading to increased protein synthesis, nitrogen retention, and muscle growth. It also exhibits weak androgenic activity and may inhibit glucocorticoid receptors.
Winstrol (stanozolol) is an anabolic steroid derived from dihydrotestosterone. It binds to androgen receptors, increasing protein synthesis and inhibiting catabolic glucocorticoid activity, leading to enhanced muscle growth and reduced inflammation.
100-200 mg intramuscularly every 2-3 weeks.
Adults: 2 mg orally three times daily, or 50 mg/mL intramuscularly once monthly (3-4 week intervals) for anabolic effect. Dose range: 1-3 mg/kg/day for hereditary angioedema.
None Documented
None Documented
Terminal elimination half-life approximately 8-10 hours, but active metabolite 19-nortestosterone has a longer half-life (~2-4 hours), necessitating frequent dosing for stable blood levels.
Terminal elimination half-life: 9-10 hours for oral administration (stanozolol); parenteral (IM) half-life extends to ~24 hours due to slow release from injection site. Clinical context: supports once-daily oral dosing or weekly IM dosing.
Primarily renal (90% as metabolites, mainly glucuronide and sulfate conjugates; 6% as unchanged drug); about 4% fecal.
Primarily renal: 90% as metabolites (glucuronide and sulfate conjugates) and 10% as unchanged drug; minor biliary/fecal elimination (<5%).
Category C
Category C
Anabolic Steroid
Anabolic Steroid